Ivabradina Fantex

Ivabradine Hydrochloride, the active ingredient in Ivabradina Fantex, is an If channel inhibitor presented as an oral tablet for oral use. It is used to manage chronic heart failure and stable angina pectoris in adult patients by lowering heart rate without affecting contractility.

GNH USA supplies Ivabradina Fantex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑compliant documentation for cross‑border procurement.

Ivabradina Fantex is indicated for conditions where reduction of heart rate improves clinical outcomes, primarily within the cardiovascular disease spectrum.

- Chronic heart failure: improves symptoms, exercise tolerance and reduces hospitalization risk. - Stable angina pectoris: decreases frequency of angina attacks and improves exercise capacity.

Ivabradina Fantex may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Phosphenes (transient visual disturbances) - Bradycardia - Headache - Dizziness

Serious or Rare Side Effects: - Symptomatic severe bradycardia - Atrial fibrillation - Marked hypotension - Allergic reactions (rash, angioedema)

When prescribing Ivabradina Fantex, clinicians should observe several safety measures.

- Heart rate monitoring: check resting heart rate before initiation and periodically thereafter. - Contraindication in severe hypotension: avoid use in patients with systolic BP <90 mmHg. - Caution in hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Interaction with other bradycardic agents: use carefully when combined with beta‑blockers or digoxin. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at room temperature: keep in original packaging, protect from moisture and light.

Ivabradina Fantex can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Concomitant use with other bradycardic agents (e.g., high‑dose beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Diltiazem and verapamil: may modestly increase ivabradine levels. - Amiodarone: potential additive effect on heart rate. - Antihypertensive drugs: may enhance blood‑pressure lowering. - Antidepressants metabolized by CYP3A4 (e.g., sertraline): monitor for increased exposure.